Drug Profile

BCX 10013

Alternative Names: BCX-10013

Latest Information Update: 13 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BioCryst Pharmaceuticals
Class Small molecules
Mechanism of Action Complement factor D inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Immunological disorders; Paroxysmal nocturnal haemoglobinuria

Most Recent Events

11 Dec 2024 BioCryst Pharmaceuticals completes a phase I trial in Paroxysmal nocturnal haemoglobinuria in Malaysia and South Africa (PO) (NCT06100900)
08 Sep 2024 Adverse event, pharmacokinetics and pharmacodynamics data from the phase I trial was presented at the 2024 American College of Clinical Pharmacology Annual Meeting (ACCP-2024)
05 Aug 2024 Discontinued - Phase-I for Immunological disorders (In volunteers) in USA (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com